Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times
Business

Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid

New Delhi: Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries -- India's largest pharmaceutical company -- over the proposed USD 11.75-billion acquisition of US-based Organon & Co.

S&P Global Ratings assigned a preliminary 'BBB+' long-term issuer credit rating, while Moody's Ratings assigned a 'Baa1' long-term issuer rating to the Indian pharmaceutical major. Both agencies have maintained a 'stable' outlook for the company.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.